7934 Government Road, Burnaby, B.C.,
V5A 2E2
Phone: (604) 551-7831 Fax: 604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix and University of Florida make significant strides
in developing benchtop FAIMS technology into a portable Cannabix
Marijuana Breathalyzer
Vancouver, BC -- November 14, 2016 -- InvestorsHub NewsWire
-- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF)
(the Company or Cannabix) developer of the Cannabix Marijuana
Breathalyzer for law enforcement and the workplace, is pleased to
release images of its Beta 2.0 Cannabix Marijuana Breathalyzer. New
images of the device can be viewed at cannabixtechnologies.com.
Cannabix has been using a methodical iterative product
development process to develop its marijuana breathalyzer.
Using this method, the product is developed in several prototype
stages with each stage used to advance the product to subsequent
stages. Cannabix has systematically moved the development of
the Cannabix Marijuana Breathalyzer from a concept stage to its
Beta 2.0 prototype. The following is a chronology of development
highlights:
- August 2015-Cannabix entered into a research and option
agreement to develop a cutting-edge breath detection sensor based
upon high-field ion mobility coupled with mass spectrometry in
collaboration with the Yost Research Group at the University of
Florida. The Yost Research Group, a world leader and pioneer
in the development of high-field asymmetric waveform
ion mobility spectrometry, known as FAIMS. Cannabix and
The Yost Research Group began working together to identify
Tetrahydrocannabinol (THC- the psychoactive component of marijuana
that causes intoxication) in ultra low ranges using highly a
sensitive FAIMS-mass spectrometer benchtop system. The Company
entered into a definitive license agreement with the University of
Florida for US Patent 8,237,118 in the summer of 2016 which
provided the Company exclusive worldwide rights in the area of
breath analysis of controlled substances.
- June 2016-Cannabix Scientists and Dr. Rick Yost at the
University of Florida developed a standalone desktop-sized Beta 1.0
FAIMS based device with a proprietary configurable high
voltage power supply which operated with conventional power
sources. The FAIMS cell employed in "Beta 1.0 device was 4X smaller
than the prior benchtop version and had achieved a 10X reduction in
power supply size, which allowed for a drastically smaller
footprint. The Beta 1.0 included a power supply that was readily
configurable for ongoing testing and was designed to integrate with
a non-radioactive ionization source.
- October 19, 2016- Cannabix developed its Beta 2.0 Cannabix
Marijuana Breathalyzer with major advances in the design and size
of the device, including: greater sensitivity, improved
performance by the square waveform generator and a much smaller
size for all components. The Beta 2.0 design included
features to allow for the addition of a rechargeable battery
and touch screen and the device is approximately 10 times
smaller than the Beta 1.0 device. Preliminary lab tests of the
FAIMS device coupled with quadrupole ion trap mass spectrometry
have shown lower levels of detection for THC standards than were
achieved in past testing.
- November 11, 2016- Cannabix provides the first images of the
Cannabix Marijuana Breathalyzer "Beta 2.0 device. Images show
components housed in a durable compact black box which has been
reduced in size to be a portable device. The device encompasses the
latest chip technology to improve speed performance, FAIMS
detection technology, conventional battery and updated square wave
generator. Cannabix believes that the Beta 2.0 Cannabix Marijuana
Breathalyzer which utilizes FAIMS detection technology is the
most sensitive and scientifically proven method of detection
of volatile compounds found at trace levels in exhaled breath.
The Beta 2.0 prototype encompasses a robust detection system and
components platform that will be used in an eventual finalized
product for manufacturing. The Beta 2.0 prototype has
provided excellent sensitivity in lab testing and will be utilized
to conduct scientific studies with live marijuana users (smokers
and edible consumers) to test the device for its accuracy and
sensitivity using a controlled scientific testing protocol. The
results of the scientific test will be used to prepare submissions
for approval of the Cannabix Marijuana Breathalyzer as a
court-approved device by the Minister of Justice in Canada and the
National Highway Traffic Safety Administration (NHTSA) in the
United States. In addition, law enforcement officials and
regulators for the Minister of Justice and the NHTSA will be
consulted regarding additional features, roadside protocol, ease of
use, and to define a final housing design for a finished
product.
The scientific testing protocol will be designed by the
Cannabixs Dr. Raj Attariwala, with input from the Companys team of
exceptional Scientific Advisors. Additional input on the
trial testing will be sought from consultants who are familiar with
obtaining regulatory approvals for court certified device from the
Minister of Justice in Canada and the NHTSA in the USA.
Professor Richard Yost, Head of Analytical Chemistry at the
University of Florida and Scientific Advisor on the FAIMS Cannabix
Marijuana Breathalyzer states:
When Cannabix first approached our lab with the goal of building
a device that could detect trace amounts of THC through exhaled
breath, we were excited to face the challenge. We have been able to
use our expertise and patent in FAIMS technology and build a device
that achieves the required sensitivity and specificity but also
will be a handheld portable device, similar to alcohol
breathalyzers. We are extremely pleased and proud to be working on
the design of a portable Cannabix Marijuana Breathalyzer that will
be used by Law Enforcement to collect evidence of impaired driving
and ensure safety on our roads as marijuana use becomes accepted in
society and its use continues to grow."
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer
development for law enforcement and the workplace. Cannabix has
established breath testing technologies in the pursuit of bringing
durable, portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects use days or even weeks earlier.
The devices will also be useful for other practical applications
such as testing employees in the workplace where intoxication by
THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
Rav Mlait
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that
involves various risks and uncertainties regarding future events.
Such forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Companys plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (v) the ability of the Company to develop and
market its future product; and (vi) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing patent pending technologies licensed by
the Company will receive patent status by regulatory authorities.
The Company is not currently selling commercial breathalyzers.
Actual results and future events could differ materially from those
anticipated in such information. These and all subsequent written
and oral forward-looking information are based on estimates and
opinions of management on the dates they are made and are expressly
qualified in their entirety by this notice. Except as required by
law, the Company does not intend to update these forward-looking
statements.